EKF Diagnostics (OTCMKTS:EKDHF – Get Free Report) is projected to release its resultson Tuesday, September 15th. Analysts expect the company to post earnings of $0.0119 per share and revenue of $33.1420 million for the quarter.
EKF Diagnostics Stock Performance
EKF Diagnostics stock opened at $0.34 on Monday. The company’s fifty day simple moving average is $0.34 and its 200-day simple moving average is $0.34. EKF Diagnostics has a 12 month low of $0.29 and a 12 month high of $0.42.
About EKF Diagnostics
EKF Diagnostics Holdings plc (OTCMKTS: EKDHF) is a global in vitro diagnostics company that develops, manufactures and markets a broad range of point-of-care and laboratory analyzers, reagents and consumables. The company’s product portfolio addresses key segments of the diagnostic testing market, including haematology, biochemistry, immunoassay, haemostasis and diabetes monitoring.
EKF Diagnostics offers peripheral blood analyzers designed for use in clinical laboratories, hospitals and veterinary clinics, along with handheld and benchtop devices for rapid on-site testing.
Read More
- Five stocks we like better than EKF Diagnostics
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for EKF Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EKF Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
